TY - JOUR
T1 - Patterns of Care and Survival for Elderly Acute Myeloid Leukemia—Challenges and Opportunities
AU - Mangaonkar, Abhishek A.
AU - Patnaik, Mrinal M.
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media New York.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Purpose of Review: Acute myeloid leukemia (AML) is a disease of the elderly, with a median age of diagnosis in the sixth decade of life. Mortality has declined over the last few years, but this impact is apparent only in the young, fit AML population. Outcomes for the elderly remain poor, with less than 20% 5-year overall survival rates. Hence, there is an unmet need to identify treatment strategies to maximize benefit in this age group. Recent Findings: Elderly AML is a difficult entity to treat due to both disease and patient-related factors. Treatment of this group has a lot of inter-physician and inter-institutional variability. Several objective criteria to assess biological age, impact of co-morbidities, and fitness have been published, which could be utilized to make management decisions. For old and unfit AML patients, a variety of novel therapeutic agents are currently being investigated. Summary: Objective analysis of biological age should include assessment of fitness, frailty, and co-morbidities in elderly AML. Future areas of research include development of an objective risk-based approach and its validation in clinical trials, development of novel therapeutic agents, and improvement in supportive care measures.
AB - Purpose of Review: Acute myeloid leukemia (AML) is a disease of the elderly, with a median age of diagnosis in the sixth decade of life. Mortality has declined over the last few years, but this impact is apparent only in the young, fit AML population. Outcomes for the elderly remain poor, with less than 20% 5-year overall survival rates. Hence, there is an unmet need to identify treatment strategies to maximize benefit in this age group. Recent Findings: Elderly AML is a difficult entity to treat due to both disease and patient-related factors. Treatment of this group has a lot of inter-physician and inter-institutional variability. Several objective criteria to assess biological age, impact of co-morbidities, and fitness have been published, which could be utilized to make management decisions. For old and unfit AML patients, a variety of novel therapeutic agents are currently being investigated. Summary: Objective analysis of biological age should include assessment of fitness, frailty, and co-morbidities in elderly AML. Future areas of research include development of an objective risk-based approach and its validation in clinical trials, development of novel therapeutic agents, and improvement in supportive care measures.
KW - Acute myeloid leukemia
KW - Allogeneic stem cell transplant
KW - Elderly AML
KW - Outcomes
KW - Patterns of care
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85020100003&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020100003&partnerID=8YFLogxK
U2 - 10.1007/s11899-017-0388-8
DO - 10.1007/s11899-017-0388-8
M3 - Review article
C2 - 28567524
AN - SCOPUS:85020100003
SN - 1558-8211
VL - 12
SP - 290
EP - 299
JO - Current Hematologic Malignancy Reports
JF - Current Hematologic Malignancy Reports
IS - 4
ER -